

Industry Insight

Indian Pharmaceuticals

December-2009

Cygnus

Business Consulting & Research Pvt.Ltd.

Knowledge Partner for Profitable Growth

Plot No. 8-3-948/949, 1st floor, Solitaire Plaza, Beside Image Hospital, Ameerpet, Hyderabad-500034, India

Tel: +91-40-23430202-05, Fax: +91-40-23430201, E-mail: info@cygnusindia.com

Website: www.cygnusindia.com

Disclaimer: All information contained in this report has been obtained from sources believed to be accurate by **Cygnus Business Consulting & Research Pvt. Ltd.** (Cygnus). While reasonable care has been taken in its preparation, Cygnus makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. The information contained herein may be changed without notice. All information should be considered solely as statements of opinion and Cygnus will not be liable for any loss incurred by users from any use of the publication or contents

SYNOPSIS

Indian Pharmaceuticals industry achieved a significant growth of 13.44% during 2004-09 due to strong internal demand and continuous focus in the global generics market and active share in the export of Active Pharmaceuticals Ingredients (API). Cygnus estimates that Indian pharmaceutical industry reached at US\$10.88 billion in 2008-09 and it is likely to double its value to US\$20.95 billion in 2014. The investment in R&D, filling of higher number of ANDAs and DMFs in highly regulated market, mergers & acquisitions, in-licensing, skilled labour force, high standard scientific base and revenues from CRAMS are expected to give necessary edge to Indian pharma companies in the coming years. The pharmaceutical exports in 2008-09 were valued at Rs. 394.59 billion as compared to Rs. 302.73 billion in 2007-08, thus growing at 30.34% higher than 2007-08. Global recession could not impact Indian pharma industry and pharma companies are bullish about demand generated from the overseas market along with stronger growth in internal demand in the near future.

In the backdrop of current growth scenario in the Indian pharma industry Cygnus has come out with an Industry Insight - Indian Pharmaceutical Industry. The report is divided into ten chapters. The report has covered global pharma industry in the beginning followed by overview of Indian pharma industry and foreign trade for the industry. It has covered total 20 leading pharma companies and also provided industry's growth drivers and issues & challenges. The report also covers outsourcing, generic opportunities for the industry. The outlook of the pharma industry is also covered in the last chapter.

The report will be useful for industry researchers, pharma companies interested in overall growth scenario of the Indian pharma industry, independent consultants for pharma industry and students and faculties of various pharma institutions.

Total No of Chapters – 10 Total No of Pages – 289 No of Figures – 37 No of Tables - 26

CONTENTS

Executive summary	16
Highlights	19
1. Industry Overview – Global and Domestic	23
1.1 Global Pharmaceutical Market.....	23
1.1.1 Leading Therapeutic Classes.....	24
1.1.2 Major Markets.....	27
1.1.3 Trends in Pharmaceutical Industry in 2009	29
1.1.4 Global M&A.....	30
1.1.5 Major Global Players	33
1.2 Indian Pharmaceutical Industry	37
1.2.1 Introduction.....	37
1.2.2 Pharmaceutical Industry Structure	38
1.2.3 Segmentation of the Indian Pharmaceutical Industry	39
1.2.4 Pharmaceutical Market structure and Size	43
1.2.5 Major Therapeutic Segments.....	49
1.2.6 Merger & Acquisition	50
1.2.7 Demand-Supply Analysis.....	55
1.2.8 Foreign Direct Investments in Indian Pharma.....	56
2. Foreign Trade in Pharmaceutical Industry.....	59
2.1 Exports.....	59
2.1.1 Country Wise Exports.....	61
2.1.2 Exports Trends	61
2.2 Imports.....	62
2.2.1 Bulk Drugs Imports.....	62
2.3 Future Outlook.....	63
3. Growth Drivers.....	65
3.1 Global Growth Drivers	66
The global growth drivers of the pharmaceutical industry are given below:.....	66
3.1.1 Innovation in Biotechnology	66
3.1.2 Demographic Transition.....	66
3.1.3 Rising Real Incomes	67
3.1.4 Medical Technology	68

3.1.5 Generic and Niche.....	68
3.1.6 Unmet Medical Needs.....	70
3.2 Indian Pharma Drivers	70
3.2.1 Ageing Population.....	71
3.2.2 Lifestyle Drugs	71
3.2.3 Healthcare Expenditure.....	72
3.2.4 Upgradation of Medical Services, Devices & Equipment.....	72
3.2.5 Exports	73
3.2.6 Generic Drugs.....	73
3.2.7 Research & Development.....	74
3.2.8 Contract Manufacturing Opportunities.....	77
3.2.9 Middle Class, Rural Market to Fuel Pharma Growth.....	77
3.2.10 Pharma Firms Betting Big on Nutraceuticals	78
4. Issues & Challenges	80
4.1 Sustaining Exports.....	80
4.2 IPR Issues	81
4.2.1 Pricing	81
4.2.2 Data protection	82
4.3 R&D Focus	82
4.3.1 Looming shortage of trained human resources	84
4.3.2 Animal trials.....	85
4.3.3 Regulatory infrastructure	85
4.3.4 Managing productivity.....	85
4.4 Exploiting Generic Opportunities requires Huge Investment	86
4.5 Price Control	86
4.6 Infrastructure	87
4.6.1 R&D infrastructure	87
4.6.2 Quality of marketing infrastructure	87
4.7 Spurious Drugs.....	88
5. Major Players.....	89
5.1 Daiichi Sankyo.....	90
5.1.1 Business Profile	90
5.1.2 Strategies.....	97

5.1.3 Financial Profile	98
5.1.4 SWOT Analysis.....	99
5.1.5 Outlook	100
5.2 Dr Reddy's Laboratories Ltd	100
5.2.1 Business Profile	100
5.2.2 Strategies.....	102
5.2.3 Financial profile.....	104
5.2.4 SWOT Analysis.....	104
5.2.5 Outlook	105
5.3 Cipla Ltd.....	106
5.3.1 Business Profile	106
5.3.2 Strategies.....	113
5.3.3 Financial Profile.....	114
5.3.4 SWOT Analysis.....	114
5.3.5 Outlook	115
5.4 Sun Pharmaceutical Industries Ltd	116
5.4.1 Business Profile	116
5.4.2 Strategies.....	117
5.4.3 Financial Profile	119
5.4.4 SWOT Analysis.....	119
5.4.5 Outlook	120
5.5 Piramal Healthcare Ltd	121
5.5.1 Business Profile	121
5.5.3 Financial Profile.....	129
5.5.4 SWOT Analysis.....	129
5.5.5 Outlook	130
5.6 Lupin Ltd	131
5.6.1 Business Profile	131
5.6.2 Strategies.....	133
5.6.3 Financial profile.....	135
5.6.4 SWOT Analysis.....	135
5.6.5 Outlook	136
5.7 Wockhardt Ltd	137
5.7.1 Business Profile	137
5.7.2 Strategies.....	138

5.7.3 Financial profile	139
5.7.4 SWOT Analysis.....	140
5.7.5 Outlook	141
5.8 Jubilant Organosys	142
5.8.1 Business Profile	142
5.8.2 Strategies.....	143
5.8.3 Financial profile.....	145
5.8.4 SWOT Analysis.....	145
5.8.5 Outlook	146
5.9 Aurobindo Pharma Ltd	147
5.9.1 Business Profile	147
5.9.2 Strategies.....	149
5.9.3 Financial profile.....	150
5.9.4 SWOT Analysis.....	150
5.9.5 Outlook	151
5.10 Cadila Healthcare Ltd	152
5.10.1 Business Profile.....	152
5.10.2 Strategies.....	158
5.10.3 Financial Profile.....	160
5.10.4 SWOT Analysis	160
5.10.5 Outlook.....	161
5.11 Glenmark Pharmaceuticals Ltd	162
5.11.1 Business Profile.....	162
5.11.2 Strategies.....	163
5.11.3 Financial Profile.....	165
5.11.4 SWOT Analysis	165
5.11.5 Outlook.....	166
5.12 Matrix Laboratories	168
5.12.1 Business Profile.....	168
5.12.2 Strategies.....	170
5.12.3 Financial Profile.....	171
5.12.4 SWOT Analysis	171
5.12.5 Outlook.....	173
5.13. GlaxoSmithKline Pharmaceuticals Ltd	174
5.13.1 Business Profile.....	174

5.13.2 Strategies.....	179
5.13.3 Financial Profile.....	180
5.13.4 SWOT Analysis	180
5.13.5 Outlook.....	181
5.14 Torrent Pharmaceuticals	182
5.14.1 Business Profile.....	182
5.14.2 Strategies.....	183
5.14.3 Financial Profile.....	184
5.14.4 SWOT Analysis	184
5.14.5 Outlook.....	185
5.15 Orchid Chemicals and Pharmaceuticals Ltd	186
5.15.1 Business Profile.....	186
5.15.2 Strategies.....	187
5.15.3 Financial Profile.....	188
5.15.4 SWOT Analysis	189
5.15.5 Outlook.....	190
5.16 Ipca Laboratories Ltd	191
5.16.1 Business Profile.....	191
5.16.2 Strategies.....	193
5.16.3 Financial Profile.....	194
5.16.4 SWOT Analysis	194
5.16.5 Outlook.....	195
5.17 Biocon Limited	196
5.17.1 Business Profile.....	196
5.17.2 Strategies.....	198
5.17.3 Financial Profile.....	199
5.17.4 SWOT Analysis	199
5.17.5 Outlook.....	200
5.18 Divis laboratories.....	202
5.18.1 Business profile.....	202
5.18.2 Strategies.....	203
5.18.3 Financial Profile.....	204
5.18.4 SWOT Analysis	204
5.18.5 Outlook.....	205
5.19 Alembic Ltd	206

5.19.1 Business Profile.....	206
5.19.2 Strategies.....	207
5.19.3 Financial Profile.....	208
5.19.4 SWOT Analysis	208
5.19.5 Outlook.....	209
5.20 Aventis Pharma Ltd.....	210
5.20.1 Business Profile.....	210
5.20.2 Strategies.....	211
5.20.3 Financial Profile.....	212
5.20.4 SWOT Analysis	212
5.20.5 Outlook.....	213
6. Outsourcing Opportunities	214
6.1 Factors Driving Outsourcing	214
6.1.1 Value Chain Optimisation	215
6.1.2 FDA-approved Manufacturing Plants in India.....	218
6.1.3 Weaker Pipelines and Rising Approval Times	218
6.1.4 Pressure to Cut Prices.....	219
6.1.5 Declining Market Exclusivity Period.....	220
6.1.6 Need to Improve Marketing Productivity.....	220
6.2 Outsourcing Market.....	221
6.2.1 Indian Market	222
6.2.2 Opportunities for Indian Pharma Companies.....	222
6.2.3 Contract Manufacturing.....	223
6.2.4 Contract Research	225
7. Generic Opportunities.....	230
7.1 Generics Market Overview	231
7.2 Factors Driving Generics Market in India.....	232
7.2.1 Cost advantage.....	233
7.2.2 Drugs going off patent.....	235
7.2.3 Rising healthcare expenditure	236
7.2.4 Growing population.....	236
7.2.5 Emerging lifestyle diseases.....	237
7.2.6 Drug Master Filing submission on the Rise	239
8. Regulatory Issues	241
8.1 Overview.....	241

8.2 Regulatory Environment	242
8.2.1 General regulations.....	242
8.3 Entry Strategies	244
8.3.1 Importing pharmaceuticals	244
8.3.2 Manufacturing under license	245
8.3.3 Entry through joint venture/subsidiary.....	245
8.3.4 Approvals for foreign companies with prior Indian exposure	246
8.3.5 Additional options.....	246
8.4 Key Legislations.....	247
8.4.1 The Drugs and Cosmetics Act, 1940.....	247
8.4.2 The Medicinal & Toilet Preparations Act, 1955 with Rules, 1956	248
8.4.3 The Drug Policy, 1986.....	249
8.4.4 The Essential Commodities Act, 1955	249
8.4.5 Indian Patents Act, 1970	249
8.4.6 The Drugs Price Control Order, 1995	250
8.4.7 Good Manufacturing Practices	250
8.4.8 The Pharmacy Act, 1948	250
8.5 Regulatory Bodies	250
8.5.1 The Drugs Controller of India	250
8.5.2 State Food and Drug Administration.....	251
8.5.3 National Pharmaceutical Pricing Authority	251
8.5.4 Department of Chemicals and Petrochemicals	252
8.5.5 Foreign Investment promotion board	253
8.5.6 Central Drugs Standard Control Organisation.....	253
8.5.7 Central Drug Authority	255
8.6 Price Controls.....	255
8.6.1 Pricing of Scheduled Bulk Drugs	256
8.6.2 Pricing of Scheduled Formulations Imported into India	257
8.6.3 Pricing Regulations	257
8.7 Intellectual Property Rights	258
8.7.1 Legal Procedure.....	259
8.7.2 Compulsory Licensing and Revocation of EMR.....	260
8.7.3 Permission for residents to apply for patents outside India.....	260
8.7.4 Trademarks.....	261
8.8 Manufacturing.....	261

8.8.1 Industrial Licensing.....	262
8.8.2 Additional Approvals/Registration.....	263
8.9 Imports.....	263
8.9.1 Imports of Capital Goods and Raw Materials.....	264
8.9.2 Pharmaceutical Imports	264
8.10 New Drug Approval Process.....	265
8.10.1 Drug Approval Procedure	265
8.11 Product Standards.....	266
8.11.1 Labelling.....	267
8.12 Tariff Structure	268
8.12.1 Local Manufacturing Duty	269
8.12.2 Sales Tax	269
8.13 Marketing and Distribution.....	270
8.13.1 Licensing of sales outlets and stock holding.....	270
8.13.2 Prescription Drugs.....	270
8.13.3 Advertisement and Promotion	271
8.13.4 Regulations of Advertising	271
8.13.5 Packing and Labelling.....	271
8.13.6 Distribution	272
8.13.7 Brands.....	272
8.13.8 Restrictive Trade Practices.....	272
8.13.9 Consumer Protection	273
9. Critical Success Factors	274
9.1 Research & Development.....	274
9.2 New Product Development	277
9.3 Therapeutic Coverage	279
9.4 Marketing	280
9.5 Exports.....	282
9.6 Critical Mass.....	283
9.7 Low-cost Production	283
9.8 World-class Practices	284
10. Future Outlook	285

Bibliography287

LIST OF CHARTS

- Figure 1.1: Global pharmaceutical market value (2003-2008)
- Figure 1.2: Percentage share of global therapeutic segment (2004-08)
- Figure 1.3: Global therapeutic segments percentage market share variation (2004-08)
- Figure 1.4: Pharmaceutical Industry Structure
- Figure 1.5: Therapeutic Segmentation
- Figure 1.6: Chronic Segment
- Figure 1.7: Acute Segment
- Figure 1.8: Indian Bulk Drugs Market (2005-09)
- Figure 1.9: Indian Pharmaceutical Market Structure
- Figure 1.10: Revenue flow in the Pharmaceutical Market
- Figure 1.11: Indian Pharmaceutical Market (2004-2009)
- Figure 1.12: Major Therapeutic Segments Contribution Percentage
- Figure 1.13: FDI in India Cumulative from Apr'00 to June 09
- Figure 1.14: FDI in Indian Pharma
- Figure 1.15: FDI in India by different countries (FY07-FY10)
- Figure 2.1: Indian Pharmaceutical Exports (FY05-09)
- Figure 2.2: Region-wise Export data (FY03-08)
- Figure 3.1: Percentage of population above 65 years
- Figure 3.2: Value of products going off patent 2009-12
- Figure 3.3: Age-wise Population Distribution
- Figure 3.4: Pattern of healthcare expenditure
- Figure 6.1: R&D value chain
- Figure 6.2: Broad categories in R&D value chain
- Figure 6.3: Average time taken for drug discovery
- Figure 6.4: FDA-approved manufacturing units in countries other than the US, 2006
- Figure 6.5: Global Pharmaceutical Outsourcing Industry
- Figure 6.6: Indian Pharmaceutical Outsourcing Market
- Figure 6.7: Indian CMO Market by Segment (2008)
- Figure 6.8: Indian CRO Market (2008)
- Figure 7.1: Global generic market (2004-09)
- Figure 7.2: Patent expires by value (2008-12)

Figure 7.3: DMF filings (Global VS India)

Figure 7.4: Country wise DMF filings (2000-08)

Figure 7.5: India ANDA Approvals as % of total approvals (2001-08)

Figure 7.6 ANDA approvals received by Indian players (2001-08)

Figure 8.1: Organisational Chart of Department of Chemical and Petrochemicals

Figure 10.1: Future outlook (FY10-14)

LIST OF TABLES

- Table 1.1: Leading Therapeutic Segments-2008
- Table 1.2: Leading brands in therapeutic segment -2008
- Table 1.3: Major Markets -2008
- Table 1.4: M&A in 2008& 2009
- Table 1.5: Net Sales of top 10 Global Pharmaceutical companies
- Table 1.6: Key therapeutic categories
- Table 1.7: Major Brands in 2008
- Table 1.8: Major Deals Announced/Completed by Indian Companies 2008 &2009
- Table 1.9: Demand – supply factors
- Table 2.1: India’s Export of drugs and Pharmaceuticals & fine chemicals (US\$million)
- Table 2.2: India’s Import of Bulk drugs by Countries (US\$ million)
- Table 2.3: India’s Import of Formulations by Countries (US\$ million)
- Table 2.4: India’s Import of Formulations by Countries (US\$ million)
- Table 3.1: Top 15 drugs going off patent in next four years
- Table 3.2:R&D Expenditure -2008-09
- Table 3.3: Deals in Collaborative Research
- Table 4.1: R&D Expenditure, 2008-09 (Rs. billion)
- Table 6.1: Leading Indian CROs
- Table 7.1: Cost comparison of 20 Branded brands and their generic counterparts
- Table 7.2: Drug patent Expires (2009)
- Table 7.3: Some Examples of Lifestyle Diseases
- Table 8.1: Functions of Central and State government
- Table 8.1: Components of Custom Tariff
- Table 8.2: Tariffs on Pharmaceuticals
- Table 8.3: Tariffs on Manufacturing
- Table 9.1: Strategic R&D Demergers
- Table 9.2: Drug in the pipeline for the domestic companies